科伦药业：公司持续加强准入、业务拓展和重点品种布局

Core Viewpoint - The company is adapting to market challenges by enhancing access, business expansion, and focusing on key product layouts despite a demand decline in the infusion and generic drug sectors [1] Group 1: Business Segments - The demand for the antibiotic segment is stabilizing, with noticeable price fluctuations; however, the company maintains a significant cost advantage [1] - The synthetic biology segment is gradually ramping up production, marking this year as the sales year for synthetic biology, with sales growth expected to accumulate over time [1] - The innovative drug segment is progressing well in research and development, with a maturing commercialization system; if negotiations with medical insurance proceed smoothly, approved products are anticipated to see rapid growth next year [1] Group 2: Strategic Outlook - The company is in a year of adjustment and recovery, preparing to restore rapid growth through strategic adjustments and capacity building [1]